VYNE Therapeutics Inc

NASDAQ:VYNE   3:59:52 PM EDT
2.70
-0.05 (-1.82%)
Products

Vyne Therapeutics Says On June 30 Received A Paragraph IV Certification Notice From Perrigo Israel Pharmaceuticals

Published: 07/02/2021 22:39 GMT
VYNE Therapeutics Inc (VYNE) - Vyne Therapeutics - on June 30 Received a Paragraph Iv Certification Notice From Perrigo Israel Pharmaceuticals.
Vyne Therapeutics - Notice Advising Perrigo Submitted to U.S. FDA an Anda for Approval to Manufacture, Sell Generic Version of Co's Product Amzeeq.
Vyne Therapeutics - Notice Alleges Challenged Patents Are Invalid, Unenforceable, Will Not Be Infringed by Commercial Manufacture of Generic Product in Perrigo’s Anda.
Vyne Therapeutics - Currently Reviewing Notice & Intends to Vigorously Defend, Enforce Intellectual Property Rights Protecting Amzeeq, As Needed.
Further Company Coverage: Prgon ((reuters.
Briefs@thomsonreuters.
Com;)).